Foster City, California
Summary
This biopharmaceutical company focuses on developing innovative medicines to address significant public health challenges, particularly in the areas of HIV, liver disease, cancer, and inflammation. It has a strong commitment to research and development, with a diverse pipeline of clinical programs aimed at improving health outcomes globally. The company also emphasizes health equity and access to medicines, particularly in resource-limited settings.
Based on content on gilead.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
27.0 years — Since Jan 1998
Web Hosting
Platform
E-Mail Provider
Proofpoint
NAICS Code
325412
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Biopharmaceuticals
2. Pharmaceutical Preparation Manufacturing
Vendor
Source
Dynatrace
TXT Record
Microsoft
TXT Record
Salesforce Marketing Cloud
TXT Record
Adobe identity provider
TXT Record
Amazon SES
TXT Record
Apple
TXT Record
Atlassian
TXT Record
DocuSign
TXT Record
Emma
TXT Record
TXT Record
Smartsheet
TXT Record
Salesforce
TXT Record
Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1998 |
|
|
|
|
|
|
|
|
|
|
|
|
1999 |
|
|
|
|
|
|
|
|
|
|
|
|
2000 |
|
|
|
|
|
|
|
|
|
|
|
|
2001 |
|
|
|
|
|
|
|
|
|
|
|
|
2002 |
|
|
|
|
|
|
|
|
|
|
|
|
2003 |
|
|
|
|
|
|
|
|
|
|
|
|
2004 |
|
|
|
|
|
|
|
|
|
|
|
|
2005 |
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
|
|
|
|
|
|
|
|
|
2007 |
|
|
|
|
|
|
|
|
|
|
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
2009 |
|
|
|
|
|
|
|
|
|
|
|
|
2010 |
|
|
|
|
|
|
|
|
|
|
|
|
2011 |
|
|
|
|
|
|
|
|
|
|
|
|
2012 |
|
|
|
|
|
|
|
|
|
|
|
|
2013 |
|
|
|
|
|
|
|
|
|
|
|
|
2014 |
|
|
|
|
|
|
|
|
|
|
|
|
2015 |
|
|
|
|
|
|
|
|
|
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
2017 |
|
|
|
|
|
|
|
|
|
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
2019 |
|
|
|
|
|
|
|
|
|
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
|
|
2021 |
|
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
|
|
|
|
|
|
|
|
|
|